Literature DB >> 6992580

Endometritis following cesarean section. A controlled study of the increased duration of hospital stay and direct cost of hospitalization.

L G Donowitz, R P Wenzel.   

Abstract

The increased hospital stay and direct costs of hospitalization as a result of postcesarean section endometritis were evaluated in a case-matched and controlled study (N = 20 in each group). Endometritis increased postcesarean section hospital stay by 3 days and increased hospital cost by $850. Fifteen to 20% of women delivered by cesarean section develop postpartum endometritis. The success of future antibiotic or surgical intervention studies in reducing this high complication rate can be more accurately evaluated by comparison with these now established parameters of morbidity and cost.

Entities:  

Mesh:

Year:  1980        PMID: 6992580

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Towards a global perspective of nosocomial infections.

Authors:  R P Wenzel
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

2.  [Comparative efficacy of antibiotic prophylaxis using cefoxitin in one or in three doses in cesarean section].

Authors:  A Masse; P Turgeon; N Gay; G Verschelden
Journal:  CMAJ       Date:  1988-05-15       Impact factor: 8.262

3.  The mortality of hospital-acquired bloodstream infections: need for a new vital statistic.

Authors:  R P Wenzel
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

4.  Surgical-site Infection Following Cesarean Section in Kano, Nigeria.

Authors:  Ta Jido; Id Garba
Journal:  Ann Med Health Sci Res       Date:  2012-01

5.  Effects on developmental outcomes after cesarean birth versus vaginal birth in Chinese children aged 1-59 months: a cross-sectional community-based survey.

Authors:  Hong Zhou; Yuan Ding; Yuning Yang; Siyu Zou; Xueqi Qu; Anqi Wang; Xi Wang; Yue Huang; Xintong Li; Xiaona Huang; Yan Wang
Journal:  PeerJ       Date:  2019-10-23       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.